| MeSH term | MeSH ID | Detail |
|---|---|---|
| Fractures, Bone | D050723 | 4 associated lipids |
| Renal Insufficiency, Chronic | D051436 | 9 associated lipids |
| Hypercalciuria | D053565 | 4 associated lipids |
| Acute Coronary Syndrome | D054058 | 11 associated lipids |
| No-Reflow Phenomenon | D054318 | 2 associated lipids |
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | D054438 | 1 associated lipids |
| Hyperphosphatemia | D054559 | 1 associated lipids |
| Osteophyte | D054850 | 2 associated lipids |
| Chronic Periodontitis | D055113 | 1 associated lipids |
| Primary Myelofibrosis | D055728 | 6 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Hofbauer LC et al. | Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. | 2002 | Eur. J. Endocrinol. | pmid:12153751 |
| Mundy GR | Metastasis to bone: causes, consequences and therapeutic opportunities. | 2002 | Nat. Rev. Cancer | pmid:12154351 |
| Lorget F et al. | Lactoferrin reduces in vitro osteoclast differentiation and resorbing activity. | 2002 | Biochem. Biophys. Res. Commun. | pmid:12163011 |
| Ulrich-Vinther M et al. | Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. | 2002 | J Bone Joint Surg Am | pmid:12177271 |
| Ohmori H et al. | Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis. | 2002 | J. Hum. Genet. | pmid:12181640 |
| Armstrong AP et al. | A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. | 2002 | J. Biol. Chem. | pmid:12185073 |
| Zou W and Bar-Shavit Z | Dual modulation of osteoclast differentiation by lipopolysaccharide. | 2002 | J. Bone Miner. Res. | pmid:12096834 |
| Koyama H et al. | Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. | 2002 | J. Bone Miner. Res. | pmid:12096835 |
| Langdahl BL et al. | Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. | 2002 | J. Bone Miner. Res. | pmid:12096838 |
| Zhang J et al. | Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. | 2002 | J. Bone Miner. Res. | pmid:12096839 |
| Treuheit MJ et al. | Inverse relationship of protein concentration and aggregation. | 2002 | Pharm. Res. | pmid:12033388 |
| Biskobing DM et al. | Novel therapeutic options for osteoporosis. | 2002 | Curr Opin Rheumatol | pmid:12118183 |
| Mizukami J et al. | Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. | 2002 | Mol. Cell. Biol. | pmid:11809792 |
| Wynne F et al. | Investigation of the genetic influence of the OPG, VDR (Fok1), and COLIA1 Sp1 polymorphisms on BMD in the Irish population. | 2002 | Calcif. Tissue Int. | pmid:12073153 |
| Lubberts E et al. | Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. | 2002 | Arthritis Rheum. | pmid:12428250 |
| Crotti TN et al. | Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. | 2002 | Ann. Rheum. Dis. | pmid:12429533 |
| Hofbauer LC and Schoppet M | Osteoprotegerin deficiency and juvenile Paget's disease. | 2002 | N. Engl. J. Med. | pmid:12432053 |
| Jono S et al. | Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. | 2002 | Circulation | pmid:12208791 |
| Sedger LM et al. | Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. | 2002 | Eur. J. Immunol. | pmid:12209637 |
| Stajszczyk M | [Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism]. | 2002 | Pol. Arch. Med. Wewn. | pmid:12600190 |
| Fahrleitner A et al. | Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status. | 2002 | Wien. Klin. Wochenschr. | pmid:12602117 |
| Yang X et al. | Protein Kinase C is a mediator of the synthesis and secretion of osteoprotegerin in osteoblast-like cells. | 2002 | Biochem. Biophys. Res. Commun. | pmid:11779130 |
| Nosaka K et al. | Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. | 2002 | Blood | pmid:11781248 |
| Takayanagi H | [Cross-talk between immune and skeletal systems]. | 2002 | Nippon Rinsho | pmid:12510352 |
| Shimizu-Ishiura M et al. | Osteoprotegerin administration reduces femural bone loss in ovariectomized mice via impairment of osteoclast structure and function. | 2002 | J Electron Microsc (Tokyo) | pmid:12455916 |
| Saidenberg Kermanac'h N et al. | Osteoprotegerin and inflammation. | 2002 Apr-Jun | Eur. Cytokine Netw. | pmid:12101070 |
| Jung K et al. | Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults. | 2002 Jul-Sep | Int. J. Biol. Markers | pmid:12408468 |
| Chong B et al. | Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. | 2003 | J. Bone Miner. Res. | pmid:14672344 |
| Nielsen KL et al. | Biglycan deficiency interferes with ovariectomy-induced bone loss. | 2003 | J. Bone Miner. Res. | pmid:14672350 |
| Amizuka N et al. | Defective bone remodelling in osteoprotegerin-deficient mice. | 2003 | J Electron Microsc (Tokyo) | pmid:14756238 |
| Fizazi K et al. | Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. | 2003 | Clin. Cancer Res. | pmid:12855635 |
| Kawana F and Sasaki T | Osteoclast differentiation and characteristic trabecular bone formation during growth plate destruction in osteoprotegerin-deficient mice. | 2003 | J Electron Microsc (Tokyo) | pmid:14756239 |
| Okuma K et al. | Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin. | 2003 | J. Virol. | pmid:12857926 |
| Cheng X et al. | The TNF receptor superfamily: role in immune inflammation and bone formation. | 2003 | Immunol. Res. | pmid:12857975 |
| Shin MM et al. | High extracellular Ca2+ alone stimulates osteoclast formation but inhibits in the presence of other osteoclastogenic factors. | 2003 | Exp. Mol. Med. | pmid:12858015 |
| Gehrke T et al. | Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening. | 2003 | Scand. J. Rheumatol. | pmid:14690142 |
| Glossop JR et al. | No association of polymorphisms in the tumor necrosis factor receptor I and receptor II genes with disease severity in rheumatoid arthritis. | 2003 | J. Rheumatol. | pmid:12858434 |
| Hampson G et al. | Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial. | 2003 | Osteoporos Int | pmid:12904840 |
| Stolina M et al. | Regulatory effects of osteoprotegerin on cellular and humoral immune responses. | 2003 | Clin. Immunol. | pmid:14697750 |
| Misra M et al. | Serum osteoprotegerin in adolescent girls with anorexia nervosa. | 2003 | J. Clin. Endocrinol. Metab. | pmid:12915674 |
| Lonergan M et al. | Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm. | 2003 | J. Clin. Endocrinol. Metab. | pmid:12915677 |
| Kapczuk K et al. | [Osteoprotegerin/RANKL/RANK system and postmenopausal osteoporosis. The possible therapeutic aspects]. | 2003 | Ginekol. Pol. | pmid:12916277 |
| Liu JZ et al. | [Co-expression of human bone morphogenetic protein-2 and osteoprotegerin in myoblast C2C12]. | 2003 | Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi | pmid:12916296 |
| Bendre MS et al. | Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. | 2003 | Bone | pmid:12919697 |
| Tabb MM et al. | Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. | 2003 | J. Biol. Chem. | pmid:12920130 |
| Park HR et al. | Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. | 2003 | J. Korean Med. Sci. | pmid:12923331 |
| Kim HH et al. | RANKL regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. | 2003 | FASEB J. | pmid:14500543 |
| Nakamura M et al. | Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. | 2003 | Endocrinology | pmid:14500574 |
| Zhang Z et al. | Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis. | 2003 | J. Immunol. | pmid:14500659 |
| Ueno Y et al. | In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. | 2003 | J. Cell. Biochem. | pmid:14505343 |
| Kaneyama K et al. | Osteoclastogenesis inhibitory factor/osteoprotegerin in synovial fluid from patients with temporomandibular disorders. | 2003 | Int J Oral Maxillofac Surg | pmid:14505625 |
| Miyahira Y et al. | Cutting edge: a potent adjuvant effect of ligand to receptor activator of NF-kappa B gene for inducing antigen-specific CD8+ T cell response by DNA and viral vector vaccination. | 2003 | J. Immunol. | pmid:14662831 |
| Seidlova-Wuttke D et al. | Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. | 2003 | Eur. J. Endocrinol. | pmid:14514351 |
| Hortobagyi GN | Novel approaches to the management of bone metastases. | 2003 | Semin. Oncol. | pmid:14613037 |
| Grigorie D et al. | Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. | 2003 | Rom J Intern Med | pmid:15526523 |
| Wagner EF and Matsuo K | Signalling in osteoclasts and the role of Fos/AP1 proteins. | 2003 | Ann. Rheum. Dis. | pmid:14532157 |
| Ueland T et al. | Growth hormone substitution increases gene expression of members of the IGF family in cortical bone from women with adult onset growth hormone deficiency--relationship with bone turn-over. | 2003 | Bone | pmid:14555269 |
| Nagata N et al. | Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population. | 2003 | Bone | pmid:14555278 |
| Koshihara Y et al. | Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture. | 2003 | J. Endocrinol. | pmid:12630919 |
| Grimaud E et al. | Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. | 2003 | Am. J. Pathol. | pmid:14578201 |
| Alvarez L et al. | Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. | 2003 | Arthritis Rheum. | pmid:12632438 |
| Bord S et al. | The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. | 2003 | Bone | pmid:12633785 |
| Coen G et al. | Serum leptin in dialysis renal osteodystrophy. | 2003 | Am. J. Kidney Dis. | pmid:14582047 |
| Garber K | Why it hurts: researchers seek mechanisms of cancer pain. | 2003 | J. Natl. Cancer Inst. | pmid:12783923 |
| Chagraoui H et al. | Expression of osteoprotegerin mRNA and protein in murine megakaryocytes. | 2003 | Exp. Hematol. | pmid:14585373 |
| Liu B et al. | Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts. | 2003 | J. Oral Pathol. Med. | pmid:12787044 |
| Eaton CL and Coleman RE | Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. | 2003 | Cancer Treat. Rev. | pmid:12787713 |
| Fahrleitner-Pammer A et al. | Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. | 2003 | Wien. Klin. Wochenschr. | pmid:12793029 |
| Dovio A et al. | Correspondence re: A. Lipton et al., Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res., 8: 2306-2310, 2002. | 2003 | Clin. Cancer Res. | pmid:12796409 |
| Flick LM et al. | Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. | 2003 | J. Orthop. Res. | pmid:12798068 |
| Khapli SM et al. | IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. | 2003 | J. Immunol. | pmid:12816992 |
| Kawase Y et al. | Bone malformations in interleukin-18 transgenic mice. | 2003 | J. Bone Miner. Res. | pmid:12817749 |
| Kikuchi T et al. | Cot/Tpl2 is essential for RANKL induction by lipid A in osteoblasts. | 2003 | J. Dent. Res. | pmid:12821717 |
| D'Elia HF et al. | Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. | 2003 | Arthritis Res. Ther. | pmid:12823855 |
| Terpos E et al. | Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. | 2003 | Blood | pmid:12689925 |
| Zheng B et al. | MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. | 2003 | Blood | pmid:12689928 |
| Moreno JL et al. | IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. | 2003 | Blood | pmid:12689929 |
| Dovio A et al. | Autocrine down-regulation of glucocorticoid receptors by interleukin-11 in human osteoblast-like cell lines. | 2003 | J. Endocrinol. | pmid:12697042 |
| Nakano M et al. | Inhibitory effect of titanium particles on osteoclast formation generated by treatment of mouse bone marrow cells with PGE2. | 2003 | Oral Dis | pmid:12657033 |
| Ra JS et al. | Osteoprotegerin inhibits proliferation of myeloid progenitor cells. | 2003 | J. Hematother. Stem Cell Res. | pmid:12662434 |
| Szalay F et al. | High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. | 2003 | J. Hepatol. | pmid:12663228 |
| Okada Y et al. | Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone. | 2003 | J. Biol. Chem. | pmid:12665515 |
| Bell NH | RANK ligand and the regulation of skeletal remodeling. | 2003 | J. Clin. Invest. | pmid:12697730 |
| Eghbali-Fatourechi G et al. | Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. | 2003 | J. Clin. Invest. | pmid:12697741 |
| Enomoto H et al. | Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene. | 2003 | J. Biol. Chem. | pmid:12697767 |
| Nakashima T et al. | RANKL and RANK as novel therapeutic targets for arthritis. | 2003 | Curr Opin Rheumatol | pmid:12707582 |
| Johnson-Pais TL et al. | Determination of a minimal region of loss of heterozygosity on chromosome 18q21.33 in osteosarcoma. | 2003 | Int. J. Cancer | pmid:12673693 |
| Zaidi M et al. | Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. | 2003 | J. Bone Miner. Res. | pmid:12674320 |
| Oyajobi BO and Mundy GR | Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. | 2003 | Cancer | pmid:12548580 |
| Croucher PI et al. | Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. | 2003 | Cancer | pmid:12548581 |
| Lipton A | Bisphosphonates and metastatic breast carcinoma. | 2003 | Cancer | pmid:12548585 |
| Demers LM | Bone markers in the management of patients with skeletal metastases. | 2003 | Cancer | pmid:12548589 |
| Body JJ et al. | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. | 2003 | Cancer | pmid:12548591 |
| Liu JZ et al. | [The OPG/RANKL/RANK system and bone resorptive disease]. | 2003 | Sheng Wu Gong Cheng Xue Bao | pmid:15971575 |
| Xing L et al. | Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. | 2003 | J. Bone Miner. Res. | pmid:12568403 |
| Cao J et al. | Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. | 2003 | J. Bone Miner. Res. | pmid:12568404 |
| Johnson-Pais TL et al. | Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis. | 2003 | J. Bone Miner. Res. | pmid:12568416 |
| Clohisy JC et al. | RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. | 2003 | J. Orthop. Res. | pmid:12568950 |
| Fahrleitner A et al. | Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. | 2003 | Bone | pmid:12584041 |
| Rude RK et al. | Magnesium deficiency: effect on bone and mineral metabolism in the mouse. | 2003 | Calcif. Tissue Int. | pmid:12370796 |